Browsing by Author "Cheng, Han-Chin"

Now showing 1 - 2 of 2

Custos Remote On-demand Healthcare Aided with Wireless Sensors and Mobile Phones
(2008)
Zao, John K.
;
Fan, Shih-Chen
;
Yang, Bing-Shiang
;
Hsu, Shang-Hwa
;
Cheng, Han-Chin
Telemonitoring and remote healthcare are two ICT techniques promise to deliver cost effective long-term healthcare services to the aging population worldwide. Anticipating an emerging market opportunity, NCTU Kannon project team is creating Custos, an open composeable platform for developing remote on-demand healthcare applications using smart phones and wireless sensor networks. Camps' is integrated readily with Internet web services and UPnP digital-home platform so that it can be used to detect abnormal health conditions through multisensor data fusion, adapt environment conditions to user needs, dispatch medical alerts and instigate remedial actions via SMS/RSS communication. Moreover, Custos is easy to program because it uses Sun SPOT and Squawk Java J2ME as its sensor/actuator hub. In this position paper, we present the design principles, system architecture and operation concepts of Custos as well as a pilot plan for clinical trials in the Geriatric Psychiatry Ward of Wei-Gong Memorial Hospital in Miaoli, Taiwan.
Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer
(2016-12-27)
Wang, Hsian-Yu
;
Chang, Yu-Ling
;
Cheng, Chun-Chun
;
Chao, Min-Wu
;
Lin, Su-I
The epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown remarkable benefits in non-small cell lung cancer (NSCLC) patients with drug-sensitive mutations in the EGFR gene. Responsive patients are usually continuously prescribed with TKIs until disease progression. Glucocorticoids (GCs) are potent homeostasis maintaining drugs and are frequently used in cancer patients to alleviate discomforts caused by anti-cancer therapies. Several previous studies reported that concomitant use of GCs may compromise the efficacy of chemo-therapeutics in patients with solid tumors. Little is known in the concomitant use of target therapy with GCs in treating NSCLC. In this study, we hypothesized that concomitant use of GCs in EGFR-TKI therapy may be detrimental and addressed this issue using cell cultures and xenograft studies followed by a retrospective population study based on data from the Taiwan national health insurance system. In cell cultures and xenograft studies, GCs were shown to unequally compromise the anti-cancer efficacy of TKIs in both PC9 and NCI-H1975 NSCLC cells models. In the retrospective population study, patients with similar disease status that were co-medicated with GCs had a significantly higher risk of disease progression.